The ClinGen Evidence Repository is an FDA-recognized human genetic variant database containing expert-curated assertions regarding variants' pathogenicity and supporting evidence summaries. [Disclaimer]


Variant: NM_000020.3(ACVRL1):c.1348A>G (p.Thr450Ala)

CA6573123

373609 (ClinVar)

Gene: ACVRL1
Condition: telangiectasia, hereditary hemorrhagic, type 2
Inheritance Mode: Autosomal dominant inheritance
UUID: ee66d277-f81c-45e5-b4b1-d2a9bc5a2faf

HGVS expressions

NM_000020.3:c.1348A>G
NM_000020.3(ACVRL1):c.1348A>G (p.Thr450Ala)
NC_000012.12:g.51919086A>G
CM000674.2:g.51919086A>G
NC_000012.11:g.52312870A>G
CM000674.1:g.52312870A>G
NC_000012.10:g.50599137A>G
NG_009549.1:g.16669A>G
ENST00000547400.6:c.1078A>G
ENST00000551576.6:c.1348A>G
ENST00000552678.2:c.1348A>G
ENST00000388922.9:c.1348A>G
ENST00000388922.8:c.1348A>G
ENST00000419526.6:c.826A>G
ENST00000547632.1:n.623A>G
ENST00000550683.5:c.1390A>G
ENST00000552678.1:c.353A>G
NM_000020.2:c.1348A>G
NM_001077401.1:c.1348A>G
NM_001077401.2:c.1348A>G

Likely Benign

Met criteria codes 1
BS1
Not Met criteria codes 1
PP3

Evidence Links 0

Expert Panel

Criteria Specification Information

Criteria Specification: ClinGen Hereditary Hemorrhagic Telangiectasia Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for ACVRL1 Version 1.0.0

Criteria Specification Approval History
Criteria Specifications for this VCEP
Evidence submitted by expert panel
Hereditary Hemorrhagic Telangiectasia VCEP
The NM_000020.3: c.1348A>G variant in ACVRL1 is a missense variant predicted to cause substitution of threonine by alanine at amino acid 450 (p.Thr450Ala). The filtering allele frequency (the lower threshold of the 95% CI of 53/10366) of the c.1348A>G variant in ACVRL1 is 0.004015 for Ashkenazi Jewish chromosomes by gnomAD v2.1.1, which is higher than the ClinGen HHT VCEP threshold (>0.002) for BS1, and therefore meets this criterion (BS1). The computational predictor REVEL gives a score of 0.245, which is neither above nor below the thresholds predicting a damaging or benign impact on ACVRL1 function. In summary, this variant meets the criteria to be classified as likely benign for autosomal dominant hereditary hemorrhagic telangiectasia based on the ACMG/AMP criteria applied, as specified by the ClinGen Hereditary Hemorrhagic Telangiectasia Variant Curation Expert Panel: BS1 (specification version 1.0.0; 1/4/2024).
Met criteria codes
BS1
The filtering allele frequency (the lower threshold of the 95% CI of 53/10366) of the c.1348A>G variant in ACVRL1 is 0.004015 for Ashkenazi Jewish chromosomes by gnomAD v2.1.1, which is higher than the ClinGen HHT VCEP threshold (>0.002) for BS1, and therefore meets this criterion (BS1).
Not Met criteria codes
PP3
The computational predictor REVEL gives a score of 0.245, which is neither above nor below the thresholds predicting a damaging or benign impact on ACVRL1 function.
Approved on: 2024-03-15
Published on: 2024-03-15
The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.
¤ Powered by BCM's Genboree.